Results 51 to 60 of about 1,385 (194)

A clinical, histological and transcriptomic characterization of a selected series of Castleman disease’s cases [PDF]

, 2023
Castleman disease (CD) is a rare lymphoproliferative disorder that includes various clinico-pathological subtypes. According to clinical course CD is divided in unicentric CD (UCD) and multicentric CD (MCD).
FRATICELLI, SARA
core  

Pulmonary Manifestations of Plasma Cell Type Idiopathic Multicentric Castleman Disease: A Clinicopathological Study in Comparison with IgG4-Related Disease [PDF]

, 2020
Plasma cell type idiopathic multicentric Castleman disease (PC-iMCD) occasionally manifests as parenchymal lung disease. This study aimed to elucidate the detailed clinicopathological features of lung lesions in PC-iMCD and compare the findings with ...
Gion, Yuka, Igawa, Takuro, Inoue, Dai, Izumozaki, Akira, Nishimura, Midori Filiz, Nishimura, Yoshito, Sato, Yasuharu, Tomita, Sakura, Ubara, Yoshifumi, Yoshino, Tadashi   +9 more
core   +1 more source

Lung transplantation for idiopathic multicentric Castleman disease: potential efficacy and tolerability of a humanized anti-interleukin-6 receptor monoclonal antibody

Surgical Case Reports, 2021
Background Idiopathic multicentric Castleman disease (iMCD) is a rare polyclonal lymphoproliferative disease caused by the overrepresentation of interleukin-6 (IL-6).
Yasuaki Tomioka, Shinji Otani, Shin Tanaka, Kazuhiko Shien, Ken Suzawa, Kentaroh Miyoshi, Hiromasa Yamamoto, Mikio Okazaki, Seiichiro Sugimoto, Masaomi Yamane, Shinichi Toyooka   +10 more
doaj   +1 more source

Castleman Disease in China: State-of-the-art Technology Before the Era of IL-6 Targeted Therapy

Xiehe Yixue Zazhi, 2023
Castleman disease (CD) is a group of rare and heterogenous hematological diseases included in the 'Rare disease catalogue' of China. Among the different clinical subtypes of CD, idiopathic multicentric Castleman disease (iMCD) is characterized by ...
ZHANG Lu, LI Jian
doaj   +1 more source

Multicentric vs. Unresectable Unicentric Castleman Disease with Active Presentation: An Orphan Rare Disease in a Young Egyptian Female Patient. A Case Report [PDF]

, 2023
Background: Castleman disease (CD) is a rare disorder that affects lymph nodes and has a wide range of associated symptoms. The affected lymph nodes show characteristic histological picture.
Ahmed E. Eladl, Alaa Elshamy, Aya Elbogdady, Basma Atef, Maged Saafan, Manal Atef, Mohamed El Bogdady, Sarah El-Sherpiny, Shaimaa El-Ashwah, Shaimaa Hendawy, Yasmine Shaaban   +10 more
core   +1 more source

Unicentric Castleman disease presenting as a longstanding axillary and chest wall mass: A case report

Clinical Case Reports, Volume 11, Issue 12, December 2023., 2023
Magnetic resonance imaging (MRI). Key clinical message Unicentric Castleman disease, particularly the hypervascular variant subtype, commonly presents as a localized lymphadenopathy without systemic symptoms. Surgical excision is often curative for this subtype, leading to a good prognosis.
Wenqing Zhou, Xing Liu, Aiming Qiu, Teng Ni, Tiangeng Dong, Lei Ding   +5 more
wiley   +1 more source

Peripheral helper-T-cell-derived CXCL13 is a crucial pathogenic factor in idiopathic multicentric Castleman disease

Nature Communications, 2023
Castleman disease (CD) is a rare lymphoproliferative disorder. Among subtypes of CD, idiopathic multicentric CD-not otherwise specified (iMCD-NOS) has a poor prognosis and its pathogenesis is largely unknown.
Takuya Harada, Yoshikane Kikushige, Toshihiro Miyamoto, Kazuko Uno, Hiroaki Niiro, Atsushi Kawakami, Tomohiro Koga, Koichi Akashi, Kazuyuki Yoshizaki   +8 more
doaj   +1 more source

Comparison of the clinical characteristics of TAFRO syndrome and idiopathic multicentric Castleman disease in general internal medicine: a 6‐year retrospective study [PDF]

, 2019
Background Although thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly (TAFRO) syndrome was first described as a variant of idiopathic multicentric Castleman disease (CD), patients with TAFRO syndrome demonstrate more aggressive ...
Fujii, Nobuharu, Hanayama, Yoshihisa, Kondo, Eisei, Nishimura, Yoshito, Otsuka, Fumio   +4 more
core   +1 more source

Siltuximab monotherapy improves progression free survival compared to rituximab-based therapies in patients with idiopathic multicentric Castleman disease; indirect comparison of studies using single-arm metanalysis method and the generalized linear mixed model. [PDF]

Ann Hematol
Siltuximab is the only approved treatment for idiopathic multicentric Castleman Disease but in many countries the only available treatment is rituximab based.
Karatisidis L, Mprotsis T, Intzes S, Zagoridis K, Vrachiolias G, Karatisidou V, Bezirgianidou Z, Liapis K, Kotsianidis I, Spanoudakis E.   +9 more
europepmc   +2 more sources

THE IMPACT OF 2017 GUUDELINES ON THE DIAGNOSIS OF IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE (iMCD): A LITERATURE REVIEW

, 2021
Idiopathic Multicentric Castleman Disease (iMCD), a disease of unknown etiology is characterized by angiofollicular hyperplasia. Many of its features, attributed to the overactivity of interleukin 6 (IL-6), can be seen in other conditions such as diseases of inflammatory, infectious or neoplastic nature.
Anwar, Ghulam Rabbani, Tahir, Danial, Ahmad, Ammar, Khattak, Zoia Ehsan, Shahzad, Muhammad Asim, Inayat, Arsalan   +5 more
openaire   +1 more source